We’re proud to partner with Sutra Medical, a bold innovator in the structural heart space, as we support the early clinical development of their Sutra Hemi-Valve TMVR system — a unique approach that challenges conventional thinking in transcatheter mitral valve replacement.

While many TMVR systems aim to replace the entire mitral valve, Sutra takes a minimally disruptive route. Their device replaces only the posterior leaflet, allowing it to coapt naturally with the patient’s native anterior leaflet. The result?

• A design that preserves native valve anatomy,
• Has a small footprint in LV, and
• Eliminates risk of LVOT obstruction — a known complication with bulkier full-replacement systems.

This “hemi-valve” concept introduces a new category within mitral valve intervention — less invasive than full TMVR, yet potentially more durable than repair-based strategies. It’s especially promising for patients with complex anatomies or high surgical risk who might otherwise be left with limited options.

At Clinical Accelerator, we are proud to help bring such differentiated technologies into first-in-human studies and support companies that seek not just to improve, but to reimagine the way structural heart disease is treated.

We look forward to the journey ahead with Sutra Medical.

Learn more at sutramedical.com